

Lilly Barbiturates

TRADE MARK

Since the original synthesis of 'Amytal' over 30 years ago, continued research by Eli Lilly & Company has resulted in a wide and selective range of barbiturates.

Included in the Lilly range of Barbiturates are:—

'Pulvules' 'SECONAL SODIUM'

brand Quinalbarbitone Sodium.

Quick onset—short duration.

$\frac{3}{4}$ gr. and $1\frac{1}{2}$ grs.

'Pulvules' 'SODIUM AMYTAL'

brand Sodium Amylobarbitone.

Medium onset and duration.

1 gr. and 3 grs.

'Pulvules' 'TUINAL'

brand Quinalbarbitone Sodium with Sodium Amylobarbitone.

Quick onset—medium duration.

$1\frac{1}{2}$ grs. and 3 grs.

Tablets 'AMYTAL'

brand Amylobarbitone.

Medium onset—moderately long duration.

$\frac{1}{8}$, $\frac{1}{4}$, $\frac{1}{2}$, $\frac{3}{4}$, and $1\frac{1}{2}$ grs.

ELI LILLY AND COMPANY LIMITED
BASINGSTOKE, ENGLAND

JOURNAL OF MENTAL SCIENCE

CONTENTS FOR JANUARY, 1956

Original Articles—	PAGE
The Relation Between Neurosis and Psychosis; by <i>D. S. Trouton, M.A., M.Sc., M.B., B.Chir., and A. E. Maxwell, M.A., B.Sc., B.Ed.</i>	1
<u>Hypnagogic Imagery and Mescaline</u> ; by <i>J. Amor Ardis, M.B., Ch.B., D.P.M., and Peter McKellar, M.A., Ph.D.</i>	22
A Clinical Trial of <u>Reserpine</u> in the Treatment of Anxiety; by <i>R. S. Ferguson, M.B., Ch.B.</i>	30
Intravenous <u>Acetyl Choline</u> Therapy in Neurosis; by <i>J. R. Hawkings, M.B., D.P.M., and R. W. Tibbetts, M.A., B.M., D.P.M.</i>	43
<u>Carbon Dioxide Inhalation</u> Therapy in Neurosis; by <i>J. R. Hawkings, M.B., D.P.M., and R. W. Tibbetts, M.A., B.M., D.P.M.</i>	52
The <u>Placebo</u> Response; by <i>R. W. Tibbetts, M.A., B.M., D.P.M., and J. R. Hawkings, M.B., D.P.M.</i>	60
<u>Cerebellar Agenesis</u> ; by <i>R. M. Stewart, M.D., F.R.C.P.</i>	67
A Contribution to the Objective Measurement of the <u>Cathartic Process</u> —I; by <i>Frieda Goldman-Eisler, Ph.D.</i>	78
Facts and Fictions in the Study of <u>Child Psychiatry</u> ; by <i>Emmanuel Miller, M.A.Cantab., F.R.C.P., D.P.M.</i>	96
<u>Hibicon</u> ; by <i>J. Hoenig, I. M. Crotty, and W. R. Chisholm-Batten</i>	105
The Problem of <u>Agnosia</u> in the Light of a Case of Pure <u>Word Deafness</u> ; by <i>R. Klein, M.D., and J. Harper, M.B.E., M.B., M.R.C.P.E., D.P.M.</i>	112
An Investigation into <u>Children</u> in an Attempt to Differentiate Between <u>Mental Defect</u> and <u>Deafness</u> ; by <i>M. E. Dawson, Ph.D., B.Sc., M. J. Evans, B.Sc., M. Reed, B.Sc., and Louis Minski, M.D., F.R.C.P.</i>	121
Prognosis in Psychiatric Disorders of the <u>Elderly</u> ; by <i>D. W. K. Kay, M.B., B.Ch., D.P.M., Vera Norris, Ph.D., M.B., Ch.B., and Felix Post, M.B., M.R.C.P., D.P.M.</i>	129
Affective Disorder Arising in the <u>Senium</u> ; by <i>Martin Roth, M.D., M.R.C.P.(Lond.), D.P.M., and D. W. K. Kay, M.A., B.M., B.Ch., D.P.M.</i>	
II. Physical Disability as an Aetiological Factor	141
<u>Chlorpromazine</u> in the Treatment of the Chronic Disturbed <u>Schizophrenic Patient</u> ; by <i>P. H. Mitchell, M.A., M.D.(Cantab.), D.P.M.</i>	151
Intensive <u>Cortisone</u> Therapy in Schizophrenia; by <i>Linford Rees, M.D., B.Sc., M.R.C.P., D.P.M., and G. M. King, M.R.C.S., L.R.C.P.</i>	155
<u>Photic Stimulation</u> , Imagery, and Alpha Rhythm; by <i>Richard H. Blum</i>	160
Metabolic Variations in <u>Manic-Depressive Psychosis</u> ; by <i>J. Dawson, M.Sc., M.B., Ch.B., R. P. Hullin, Ph.D., M.Sc., A.R.I.C., and Beatrice M. Crocket, M.B., Ch.B., D.Psych.</i>	168
<u>Iron and Calcium</u> in <u>Sturge-Weber Disease</u> ; by <i>A. H. Tingey, M.A.</i>	178
Bibliography and Epitome	181